Mammalian Target Rapamycin Inhibition for Proliferative Vitreoretinopathy

Mammalian Target Rapamycin Inhibition for Proliferative Vitreoretinopathy

Interview with Ehsan Rahimy, MD, author of Mammalian Target Rapamycin Inhibition as a Therapeutic Target for Prevention of Proliferative Vitreoretinopathy. Hosted by Neil Bressler, MD.

Related Content:

Episoder(127)

Validation of a Prediction Algorithm for Progression to Advanced Macular Degeneration Subtypes

Validation of a Prediction Algorithm for Progression to Advanced Macular Degeneration Subtypes

Interview with Johanna M. Seddon, MD, ScM, author of Validation of a Prediction Algorithm for Progression to Advanced Macular Degeneration Subtypes

14 Feb 201311min

Risk Alleles in CFH and ARMS2 and the Long-term Natural History of Age-Related Macular Degeneration

Risk Alleles in CFH and ARMS2 and the Long-term Natural History of Age-Related Macular Degeneration

Interview with Ronald Klein, MD, MPH, author of Risk Alleles in CFH and ARMS2 and the Long-term Natural History of Age-Related Macular Degeneration

9 Nov 20126min

The Ophthalmic Practice of the Future

The Ophthalmic Practice of the Future

Interview with Marilyn B. Mets, MD, author of The Ophthalmic Practice of the Future.

10 Sep 201211min

Improving Preterm Ophtalmologic Care in the Era of Accountable Care Organizations

Improving Preterm Ophtalmologic Care in the Era of Accountable Care Organizations

Interview with C. Jason Wang, MD, PhD, author of Improving Preterm Ophtalmologic Care in the Era of Accountable Care Organizations.

9 Jul 201212min

Relationship of Fuchs Endothelial Corneal Dystrophy Severity to Central Corneal Thickness

Relationship of Fuchs Endothelial Corneal Dystrophy Severity to Central Corneal Thickness

Interview with Jonathan H. Lass, MD, author of Relationship of Fuchs Endothelial Corneal Dystrophy Severity to Central Corneal Thickness

9 Apr 20126min

Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years

Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years

Interview with Samuel G. Jacobson, MD, PhD, author of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years

9 Jan 20127min

Outcomes of Integrating Genetics in Management of Patients With Retinoblastoma

Outcomes of Integrating Genetics in Management of Patients With Retinoblastoma

Interview with Patricia Chévez-Barrios, MD, author of Outcomes of Integrating Genetics in Management of Patients With Retinoblastoma

14 Nov 201110min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
jss
rekommandert
forskningno
sinnsyn
tomprat-med-gunnar-tjomlid
villmarksliv
rss-paradigmepodden
rss-nysgjerrige-norge
liberal-halvtime
nevropodden
fjellsportpodden
kvinnehelsepodden
diagnose
tidlose-historier
rss-inn-til-kjernen-med-sunniva-rose
psykopoden
nordnorsk-historie
rss-hoyt-lavt-med-ida-tonseth